Bank of New York Mellon Corp Raises Holdings in SAGE Therapeutics Inc (SAGE)  Alanna Baker | Aug 17th, 2018
Bank of New York Mellon Corp grew its stake in shares of SAGE Therapeutics Inc (NASDAQ:SAGE) by 7.6% in the 2nd quarter, Holdings Channel reports. The fund owned 1,564,548 shares of the biopharmaceutical company's stock after purchasing an additional 110,134 shares during the quarter. Bank of New York Mellon Corp's holdings in SAGE Therapeutics were worth $244,898,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds also recently modified their holdings of SAGE. BlackRock Inc. raised its position in shares of SAGE Therapeutics by 9.6% in the first quarter. BlackRock Inc. now owns 3,774,283 shares of the biopharmaceutical company's stock valued at $607,923,000 after buying an additional 330,112 shares in the last quarter. OppenheimerFunds Inc. raised its position in shares of SAGE Therapeutics by 5.7% in the first quarter. OppenheimerFunds Inc. now owns 1,563,778 shares of the biopharmaceutical company's stock valued at $251,876,000 after buying an additional 84,247 shares in the last quarter. Palo Alto Investors LP raised its position in shares of SAGE Therapeutics by 0.9% in the first quarter. Palo Alto Investors LP now owns 818,331 shares of the biopharmaceutical company's stock valued at $131,809,000 after buying an additional 7,525 shares in the last quarter. Jennison Associates LLC raised its position in shares of SAGE Therapeutics by 1.8% in the second quarter. Jennison Associates LLC now owns 805,361 shares of the biopharmaceutical company's stock valued at $126,063,000 after buying an additional 14,338 shares in the last quarter. Finally, Northern Trust Corp raised its position in shares of SAGE Therapeutics by 11.1% in the first quarter. Northern Trust Corp now owns 493,595 shares of the biopharmaceutical company's stock valued at $79,503,000 after buying an additional 49,437 shares in the last quarter. Get SAGE Therapeutics alerts:
A number of equities research analysts have recently weighed in on the stock. BidaskClub upgraded shares of SAGE Therapeutics from a "sell" rating to a "hold" rating in a research report on Monday, May 14th. Piper Jaffray Companies assumed coverage on shares of SAGE Therapeutics in a research report on Monday, August 6th. They issued an "overweight" rating and a $206.00 price target for the company. ValuEngine upgraded shares of SAGE Therapeutics from a "buy" rating to a "strong-buy" rating in a research report on Wednesday, May 2nd. Canaccord Genuity reiterated a "buy" rating and issued a $210.00 price target on shares of SAGE Therapeutics in a research report on Thursday, May 3rd. Finally, Cowen reiterated a "buy" rating and issued a $207.00 price target on shares of SAGE Therapeutics in a research report on Thursday, June 14th. Two analysts have rated the stock with a sell rating, fifteen have given a buy rating and one has assigned a strong buy rating to the stock. SAGE Therapeutics currently has an average rating of "Buy" and a consensus target price of $199.19.
Shares of NASDAQ:SAGE opened at $149.05 on Friday. The company has a market capitalization of $6.92 billion, a P/E ratio of -21.02 and a beta of 2.88. SAGE Therapeutics Inc has a 1 year low of $59.57 and a 1 year high of $195.97.
SAGE Therapeutics (NASDAQ:SAGE) last announced its quarterly earnings data on Tuesday, August 7th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.84) by $1.48. The firm had revenue of $90.00 million during the quarter. equities analysts anticipate that SAGE Therapeutics Inc will post -7.86 EPS for the current fiscal year.
About SAGE Therapeutics
Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate comprises brexanolone, a proprietary intravenous formulation of allopregnanolone that has completed III clinical trials for the treatment of post-partum depression (PPD).
Read More: What is the NASDAQ Stock Market?
Want to see what other hedge funds are holding SAGE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SAGE Therapeutics Inc (NASDAQ:SAGE). SAGE Therapeutics SAGE Therapeutic